J Vet Sci.  2017 Dec;18(4):431-437. 10.4142/jvs.2017.18.4.431.

Pharmacokinetics of tilmicosin in healthy pigs and in pigs experimentally infected with Haemophilus parasuis

• Zhang L
• Zhao L
• Liu Y
• Liu J
• Li X

• KMID: 2398501
• DOI: http://doi.org/10.4142/jvs.2017.18.4.431

Abstract

A comparative in vivo pharmacokinetic (PK) study of tilmicosin (TIL) was conducted in 6 crossbred healthy pigs and 6 crossbred pigs infected with Haemophilus (H.) parasuis following oral administration of a single 40 mg/kg dose. The infected model was established by intranasal inoculation and confirmed by clinical signs, blood biochemistry, and microscopic examinations. Plasma TIL concentrations were determined by a validated high-performance liquid chromatography method with ultraviolet detection at 285 nm. PK parameters were calculated by using WinNonlin software. After TIL administration, the main PK parameters of TIL in healthy and H. parasuis-infected pigs were as follows: Area under the concentration-time curve, maximal drug concentration, half-life of the absorption phase, half-life of the distribution phase, and half-life of the elimination phase were 34.86 ± 9.69 vs. 28.73 ± 6.18 µg · h/mL, 1.77 ± 0.33 vs. 1.67 ± 0.28 µg/mL, 2.27 ± 0.45 vs. 2.24 ± 0.44 h, 5.35 ± 1.40 vs. 4.61 ± 0.35 h, and 43.53 ± 8.17 vs. 42.05 ± 9.36 h, respectively. These results of this exploratory study suggest that there were no significant differences between the PK profiles of TIL in the healthy and H. parasuis-infected pigs.

Keyword

Haemophilus parasuis; high pressure liquid chromatography; infected pigs; pharmacokinetics; tilmicosin

MeSH Terms

Absorption
Administration, Oral
Biochemistry
Chromatography, Liquid
Haemophilus parasuis*
Haemophilus*
Half-Life
Methods
Pharmacokinetics*
Plasma
Swine*

Figure

• 

  Fig. 1 Histopathological image of pig lung at 48 h after intranasal inoculation with Haemophilus parasuis (left) or sterilized saline (right). H&E stain. 400×.

• 

  Fig. 2 Semi-logarithmic plot of tilmicosin (TIL) concentration following oral administration of a single dose of 40 mg/kg body weight in healthy pigs and pigs infected with Haemophilus parasuis. Drugs concentrations are presented as means ± SD (n = 6).

Reference

1. Aarestrup FM, Seyfarth AM, Angen Ø. Antimicrobial susceptibility of Haemophilus parasuis and Histophilus somni from pigs and cattle in Denmark. Vet Microbiol. 2004; 101:143–146.

2. Ayling RD, Baker SE, Pleek ML, Simon AJ, Nicholas RAJ. Comparison of in vitro activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against recent field isolates of Mycoplasma bovis. Vet Rec. 2000; 146:745–747.

3. Buxton ILO, Benet LZ. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism and elimination. In : Brunton LL, Chabner BA, Knollmannn BC, editors. Goodman & Giman's The Pharmacological Basis of Therapeutics. 12 ed. New York: McGraw-Hill;2011.

4. Clark C, Dowling PM, Ross S, Woodbury M, Boison JO. Pharmacokinetics of tilmicosin in equine tissues and plasma. J Vet Pharmacol Ther. 2008; 31:66–70.

5. Dayao DA, Kienzle M, Gibson JS, Blackall PJ, Turni C. Use of a proposed antimicrobial susceptibility testing method for Haemophilus parasuis . Vet Microbiol. 2014; 172:586–589.

6. DeRosa DC, Veenhuizen MF, Bade DJ, Shryock TR. In vitro susceptibility of porcine respiratory pathogens to tilmicosin. J Vet Diagn Invest. 2000; 12:541–546.

7. Frank GH, Briggs RE, Loan RW, Purdy CW, Zehr ES. Effects of tilmicosin treatment on Pasteurella haemolytica organisms in nasal secretion specimens of calves with respiratory tract disease. Am J Vet Res. 2000; 61:525–529.

8. Gorham PE, Carroll LH, McAskill JW, Watkins LE, Ose EE, Tonkinson LV, Merrill JK. Tilmicosin as a single injection treatment for respiratory disease of feedlot cattle. Can Vet J. 1990; 31:826–829.

9. Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang SL, Zhou WZ. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther. 2009; 32:116–123.

10. Hansen MS, Pors SE, Jensen HE, Bille-Hansen V, Bisgaard M, Flachs EM, Nielsen OL. An investigation of the pathology and pathogens associated with porcine respiratory disease complex in Denmark. J Comp Pathol. 2010; 143:120–131.

11. Ibrahim AE, Abdel-Daim MM. Modulating effects of Spirulina platensis against tilmicosin-induced cardiotoxicity in mice. Cell J. 2015; 17:137–144.

12. Kang S, Li Z, Yin Z, Jia R, Song X, Li L, Chen Z, Peng L, Qu J, Hu Z, Lai X, Wang G, Liang X, He C, Yin L. The antibacterial mechanism of berberine against Actinobacillus pleuropneumoniae. Nat Prod Res. 2015; 29:2203–2206.

13. Keleş O, Bakirel T, Şener S, Baktir G, Daǧoǧlu G, Özkan O. [Pharmacokinetics and tissue levels of tilmicosin in fowls]. Turk J Vet Anim Sci. 2001; 25:629–634. Turkish.

14. Li X, Xie S, Pan Y, Qu W, Tao Y, Chen D, Huang L, Liu Z, Wang Y, Yuan Z. Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. Colloids Surf B Biointerfaces. 2016; 141:634–642.

15. Lindecrona RH, Friis C, Nielsen JP. Pharmacokinetics and penetration of danofloxacin into the gastrointestinal tract in healthy and in Salmonella typhimurium infected pigs. Res Vet Sci. 2000; 68:211–216.

16. Liu J, Fung KF, Chen Z, Zeng Z, Zhang J. Pharmacokinetics of florfenicol in healthy pigs and in pigs experimentally infected with Actinobacillus pleuropneumoniae. Antimicrob Agents Chemother. 2003; 47:820–823.

17. MacInnes JI, Paradis MA, Vessie GH, Slavic L, Watson S, Wilson JB, Aramini JJ, Dick CP. Efficacy of prophylactic tilmicosin in the control of experimentally induced Haemophilus parasuis infection in pigs. J Swine Health Prod. 2003; 11:174–180.

18. Modric S, Webb AI, Davidson M. Effect of respiratory tract disease on pharmacokinetics of tilmicosin in rats. Lab Anim Sci. 1999; 49:248–253.

19. Naccari F, Giofrè F, Pellegrino M, Calò M, Licata P, Carli S. Effectiveness and kinetic behaviour of tilmicosin in the treatment of respiratory infections in sheep. Vet Rec. 2001; 148:773–776.

20. Oliveira S, Blackall PJ, Pijoan C. Characterization of the diversity of Haemophilus parasuis field isolates by use of serotyping and genotyping. Am J Vet Res. 2003; 64:435–442.

21. Oliveira S, Pijoan C, Morrison R. Evaluation of Haemophilus parasuis control in the nursery using vaccination and controlled exposure. J Swine Health Prod. 2004; 12:123–128.

22. Ramadan A. Pharmacokinetics of tilmicosin in serum and milk of goats. Res Vet Sci. 1997; 62:48–50.

23. Rassouli A, Al-Qushawi A, Atyabi F, Peighambari SM, Esfandyari-Manesh M, Shams GR. Pharmacokinetics and bioavailability of three promising tilmicosin-loaded lipid nanoparticles in comparison with tilmicosin phosphate following oral administration in broiler chickens. Turk J Vet Anim Sci. 2016; 40:540–547.

24. Sang K, Hao H, Huang L, Wang X, Yuan Z. Pharmacokinetic-pharmacodynamic modeling of enrofloxacin against Escherichia coli in broilers. Front Vet Sci. 2015; 2:80.

25. Shen J, Li C, Jiang H, Zhang S, Guo P, Ding S, Li X. Pharmacokinetics of tilmicosin after oral administration in swine. Am J Vet Res. 2005; 66:1071–1074.

26. Thompson T, Darby J, Moran J, Tonkinson L, Blais J, Chamberlain S. Proceedings of the 6th International Congress of the European Association for Veterinary Pharmacology and Therapeutics. 7-11 August 1994; Edinburgh, UK.

27. Vahle JL, Haynes JS, Andrews JJ. Experimental reproduction of Haemophilus parasuis infection in swine: clinical, bacteriological, and morphologic findings. J Vet Diagn Invest. 1995; 7:476–480.

28. van Miert A. Influence of febrile disease on the pharmacokinetics of veterinary drugs. Annal Vet Res. 1990; 21:Suppl 1. 11S–28S.

29. Wang C, Zhao M, Liu YR, Luan X, Guan YY, Lu Q, Yu DH, Bai F, Chen HZ, Fang C. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature. Biomaterials. 2014; 35:1215–1226.

30. Zhang P, Hao H, Li J, Ahmad I, Cheng G, Chen D, Tao Y, Huang L, Wang Y, Dai M. The epidemiologic and pharmacodynamic cutoff values of tilmicosin against Haemophilus parasuis. Front Microbiol. 2016; 7:385.

31. Zhou X, Xu X, Zhao Y, Chen P, Xuan Z, Chen H, Cai X. Distribution of antimicrobial resistance among different serovars of Haemophilus parasuis isolates. Vet Microbiol. 2010; 141:168–173.